FDA approves JNJ’s combination therapy for patients with a type of lung cancer

(Reuters) – The FDA said on Friday it has approved Johnson & Johnson’s therapy in combination with other chemotherapies for the first-line treatment of a type of lung cancer.

(Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber)